- Open Access
Autoimmunity induced by human cytomegalovirus in patients with systemic lupus erythematosus
Arthritis Research & Therapyvolume 14, Article number: 101 (2012)
Human cytomegalovirus is a common herpesvirus that is linked to autoimmunity, especially in genetically predisposed persons. The article by Hsieh and colleagues in a previous issue of Arthritis Research & Therapy suggests that a C-terminal peptide of the human cytomegalovirus protein pp65 is highly immunogenic in patients with systemic lupus erythematosus and that antibodies against this peptide cross-react with nuclear proteins and double-stranded DNA, which are highly frequent autoantibodies in systemic lupus erythematosus patients. These observations highlight the fact that immunization with one small cytomegalovirus-specific peptide results in multiple autoreactive antibodies, probably through molecular mimicry and epitope spreading, in genetically predisposed persons.
In healthy people, a primary infection with human cytomegalovirus (HCMV) is often mild or even asymptomatic, but may cause a mononucleosis-like syndrome with fever, arthralgia, fatigue, thrombocytopenia, and anemia. During acute infection, HCMV infection often leads to immune dysfunction, including both immunosuppression and autoimmune phenomena. HCMV infection results in production of autoantibodies, mainly against endothelial cells and smooth muscle cells, although anti-nuclear, anti-phospholipid, and anti-CD13 autoantibodies are also common. Emerging evidence implies that HCMV can precede the onset of auto-immune disease, and this is probably more common in individuals predisposed for autoimmunity.
In a previous issue of Arthritis Research & Therapy, Hsieh and colleagues demonstrate that a majority of systemic lupus erythematosus (SLE) patients have antibodies to the C-terminus of pp65, in particular to the subfragment pp65336-439 . Immune reactivity against this peptide was found in 14 to 20% of patients with rheumatoid arthritis, Sjögren's syndrome, and systemic sclerosis but in only 4% of healthy controls. Immunization of BALB/c mice with pp65336-439 and C3b adjuvant resulted in production of multiple antibodies that recognize nuclear structures, including chromatin, centriole mitotic spindle type I/II, and double-stranded DNA, and the immunized mice had immunoglobulin deposition in kidney glomeruli . Previously, this group showed that pp65 immunization induces early autoantibody production and glomerulonephritis in lupus-prone mice. These observations suggest that the HCMV pp65336-439 peptide elicits production of antibodies that cross-react with nuclear proteins and are pathogenic in genetically susceptible persons.
HCMV is a ubiquitous pathogen that infects 60 to 90% of the world's population. After a primary infection, it resides in latently infected monocytes or premonocytic cells, and reactivation often driven by inflammation may occur periodically (reviewed in ). Even though the virus may not trigger autoimmune disease, it may be reactivated by an initial inflammatory insult and thereafter sustain and exacerbate inflammatory processes by producing type I cytokines and by specific mechanisms that induce inflammation and autoimmune reactions. For example, HCMV infection induces expression of cyclo-oxygenase-2 and 5-lipoxygenase and induces production of prostaglandin E2, leukotriene B4, and IL-6 - all potent inflammatory mediators [3–5]. HCMV proteins alone will also drive immune reactions to nonself-peptides. By definition, autoimmune reactions occur in the absence of a pathogen in the affected organ. Emerging evidence, however, suggests that HCMV proteins are common in tissues affected by autoimmunity and that both molecular mimicry and viral antigens may sustain immune reactions.
Active HCMV infections are indeed frequent in patients with SLE, and the virus has been implicated in both development and progression of the disease (reviewed in ). Cytomegalovirus RNA has been detected in endothelial cells in skin biopsies from patients with autoimmune sclerosis, and HCMV infection is associated with higher disease activity scores in SLE patients . Other autoimmune disorders linked to HCMV include vasculitis and scleroderma, rheumatoid arthritis, myositis, Guillan- Barré syndrome, Wegner's granulomatosis, psoriasis, and inflammatory bowel diseases . HCMV may lead to autoimmunity through molecular mimicry, epitope spreading, and an induced immune response to cryptic antigens not normally visible to the immune system.
The protein pp65 is an immunodominant T-cell epitope. During acute infection this protein generally elicits production of pp65-specific antibodies, which are apparently highly prevalent in SLE patients but poorly sustained in otherwise healthy people. Clearly, genetic susceptibility is linked to virus-induced autoimmunity and to genes encoding major histocompatibility complex and to other immune regulatory genes. For example, Toll-like receptor (TLR) 3, TLR7, and TLR9, which induce type I interferons upon ligand binding, have been associated with SLE . In lupus-prone mice, TLR3, TLR7, and TLR9 signaling is required for optimal production of IgG autoantibodies and IgM rheumatoid factor . Mice deficient in TLR7/9 signaling or lacking TLR3 exhibit a poor immune response to murine cytomegalovirus infection and increased mortality . HCMV directly triggers plasmacytoid dendritic cells to interact with TLR7 and or TLR9 and produce IFNα, which stimulates B cells . Mutations in TLR3 increase the risk of herpes simplex virus-1 encephalitis, and carriers of a hypofunctional mutation (L412F) in the TLR3 gene have reduced activation of NF-κB and IFNγ secretion, which is highly associated with severe cytomegalovirus infections, chronic candida infections, recurrent sinusitis, and hematopoietic autoimmune disorders .
Poor immune control of cytomegalovirus may thus lead to sustained periods of infection, and hyperfunctional TLR phenotypes may enhance the risk of autoimmunity. We followed a previously healthy woman with a primary HCMV infection who had abrupt onset of encephalitis associated with autoimmune phenomena. The patient had a TLR polymorphism and high serum levels of IFNγ but extremely low levels of cytomegalovirus-specific CD4 and CD8 T cells and developed several types of autoantibodies (X Xu, P Bergman, T Willows, C Tammik; M Sund, T Hofkelt, C Soderberg-Naucler, S Varani, manuscript submitted). Prolonged treatment with ganciclovir and intravenous immunoglobulins allowed for decreasing doses of cortisone, and her neurological status improved. The findings in this case suggest that cytomegalovirus infection in subjects with potentially hidden immune defects can enhance viral replication, triggering autoimmune phenomena, and that antiviral therapy may provide beneficial effects in such individuals.
Of note, Hsieh and colleagues did not observe sustained autoantibody production in mice immunized with Freund's adjuvant, but did in mice immunized with C3b ; and HCMV-induced autoimmunity has been described when co-infections by other pathogens were present that may enhance complement activation and the immune response . In summary, HCMV may be an important trigger of autoimmunity in genetically susceptible persons, perhaps especially in patients with SLE who develop HCMV-specific antibodies that recognize nuclear structures and double-stranded DNA, which are highly prevalent in these patients. Their hyperfunctional phenotype with regards to high IFNα levels connects to TLR functions, which may explain the genetic susceptibility of HCMV-induced pathologies in this patient group.
systemic lupus erythematosus
Hsieh AH, Jhou YJ, Liang CT, Chang M, Wang SL: Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice. Arthritis Res Ther. 2011, 13: R162-10.1186/ar3481.
Varani S, Landini MP: Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae. 2011, 2: 6-10.1186/2042-4280-2-6.
Qiu H, Straat K, Rahbar A, Wan M, Soderberg-Naucler C, Haeggstrom JZ: Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells. J Exp Med. 2008, 205: 19-24. 10.1084/jem.20070201.
Zhu H, Cong JP, Yu D, Bresnahan WA, Shenk TE: Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci USA. 2002, 99: 3932-3937. 10.1073/pnas.052713799.
Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, Fraile-Ramos A, Lira SA, Soderberg-Naucler C, Smit MJ: HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal. 2010, 3: ra58-10.1126/scisignal.2001180.
Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN: TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007, 13: 543-551. 10.1038/nm1590.
Kono DH, Haraldsson MK, Lawson BR, Pollard KM, Koh YT, Du X, Arnold CN, Baccala R, Silverman GJ, Beutler BA, Theofilopoulos AN: Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci USA. 2009, 106: 12061-12066. 10.1073/pnas.0905441106.
Bessou G, Traub S, Robbins SH, Uematsu S, Akira S, Alexopoulou L, Dalod M: Cutting edge: overlapping functions of TLR7 and TLR9 for innate defense against a herpesvirus infection. J Immunol. 2008, 180: 5799-5803.
Varani S, Cederarv M, Feld S, Tammik C, Frascaroli G, Landini MP, Soderberg-Naucler C: Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. J Immunol. 2007, 179: 7767-7776.
Nahum A, Dadi H, Bates A, Roifman CM: The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J Allergy Clin Immunol. 2011, 127: 528-531. 10.1016/j.jaci.2010.09.031.
Varani S, Mastroianni A, Frascaroli G, Tammik C, Rahbar A, Christensson M, Rossini G, Landini MP, Soderberg-Naucler C: Generalized Wegener's granulomatosis in an immunocompetent adult after cytomegalovirus mononucleosis and bacterial urinary tract infection. Arthritis Rheum. 2009, 60: 1558-1562. 10.1002/art.24487.
The author declares that they have no competing interests.